Raymond James & Associates Increases Stock Position in LeMaitre Vascular, Inc. (NASDAQ:LMAT)

Raymond James & Associates grew its position in shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT) by 13.3% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund owned 28,125 shares of the medical instruments supplier’s stock after purchasing an additional 3,298 shares during the quarter. Raymond James & Associates owned approximately 0.13% of LeMaitre Vascular worth $1,596,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Captrust Financial Advisors grew its stake in LeMaitre Vascular by 555.3% during the 1st quarter. Captrust Financial Advisors now owns 616 shares of the medical instruments supplier’s stock worth $29,000 after buying an additional 522 shares during the last quarter. BluePath Capital Management LLC acquired a new stake in shares of LeMaitre Vascular in the third quarter valued at approximately $31,000. FMR LLC grew its position in shares of LeMaitre Vascular by 111.7% during the first quarter. FMR LLC now owns 633 shares of the medical instruments supplier’s stock worth $33,000 after acquiring an additional 334 shares during the last quarter. DekaBank Deutsche Girozentrale acquired a new position in shares of LeMaitre Vascular in the 3rd quarter valued at $38,000. Finally, Tower Research Capital LLC TRC raised its position in LeMaitre Vascular by 241.1% in the 1st quarter. Tower Research Capital LLC TRC now owns 1,354 shares of the medical instruments supplier’s stock valued at $70,000 after purchasing an additional 957 shares during the last quarter. Institutional investors and hedge funds own 84.64% of the company’s stock.

Insider Activity at LeMaitre Vascular

In other LeMaitre Vascular news, Director Lawrence J. Jasinski sold 5,110 shares of the stock in a transaction on Tuesday, March 5th. The stock was sold at an average price of $67.50, for a total value of $344,925.00. Following the completion of the transaction, the director now owns 5,309 shares in the company, valued at $358,357.50. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. In related news, Director Lawrence J. Jasinski sold 5,110 shares of the business’s stock in a transaction dated Tuesday, March 5th. The shares were sold at an average price of $67.50, for a total transaction of $344,925.00. Following the sale, the director now owns 5,309 shares of the company’s stock, valued at $358,357.50. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CFO Joseph P. Pellegrino, Jr. sold 36,967 shares of the company’s stock in a transaction dated Thursday, February 29th. The stock was sold at an average price of $69.76, for a total transaction of $2,578,817.92. Following the transaction, the chief financial officer now owns 6,452 shares in the company, valued at $450,091.52. The disclosure for this sale can be found here. Insiders have sold a total of 114,036 shares of company stock worth $7,873,749 over the last three months. 12.40% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

Several research analysts have issued reports on LMAT shares. StockNews.com downgraded shares of LeMaitre Vascular from a “buy” rating to a “hold” rating in a research report on Tuesday. KeyCorp started coverage on LeMaitre Vascular in a report on Tuesday, February 6th. They set a “sector weight” rating on the stock. Finally, Barrington Research boosted their price target on LeMaitre Vascular from $66.00 to $69.00 and gave the company an “outperform” rating in a research report on Wednesday, February 28th. Three equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. According to MarketBeat.com, LeMaitre Vascular presently has an average rating of “Moderate Buy” and an average target price of $68.20.

LeMaitre Vascular Stock Performance

Shares of LeMaitre Vascular stock opened at $62.62 on Friday. LeMaitre Vascular, Inc. has a one year low of $44.27 and a one year high of $74.64. The company has a market cap of $1.40 billion, a P/E ratio of 46.73, a PEG ratio of 2.76 and a beta of 0.87. The firm has a fifty day moving average of $65.06 and a two-hundred day moving average of $57.79.

LeMaitre Vascular (NASDAQ:LMAT) last posted its quarterly earnings results on Tuesday, February 27th. The medical instruments supplier reported $0.38 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.36 by $0.02. The firm had revenue of $48.90 million during the quarter, compared to analysts’ expectations of $49.01 million. LeMaitre Vascular had a net margin of 15.56% and a return on equity of 10.57%. The firm’s revenue for the quarter was up 19.3% on a year-over-year basis. During the same period in the prior year, the company posted $0.25 earnings per share. As a group, equities analysts predict that LeMaitre Vascular, Inc. will post 1.66 earnings per share for the current year.

LeMaitre Vascular Increases Dividend

The firm also recently declared a quarterly dividend, which was paid on Thursday, March 28th. Stockholders of record on Thursday, March 14th were issued a $0.16 dividend. This is a boost from LeMaitre Vascular’s previous quarterly dividend of $0.14. This represents a $0.64 annualized dividend and a dividend yield of 1.02%. The ex-dividend date of this dividend was Wednesday, March 13th. LeMaitre Vascular’s dividend payout ratio (DPR) is currently 47.76%.

About LeMaitre Vascular

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.